|
|
||||||||
-induced endothelium-independent vasodilation: a role
for phospholipase A2-dependent
ceramide signaling
Department of Physiology, University of Michigan, Ann Arbor, Michigan 48109
| |
ABSTRACT |
|---|
|
|
|---|
Ceramide is a novel second messenger generated
by hydrolysis of membrane sphingomyelin by a neutral sphingomyelinase
(nSMase). Cytokines such as tumor necrosis factor-
(TNF-
) have
been shown to increase intracellular ceramide through phospholipase
A2
(PLA2)-dependent activation of
nSMase. TNF-
has been shown to cause endothelium-independent relaxation in isolated blood vessels. We have previously shown that
exogenously applied sphingomyelinase and ceramide cause
endothelium-independent vasodilation in rat thoracic aortas (D. G. Johns, H. Osborn, and R. C. Webb. Biochem. Biophys.
Res. Commun. 237: 95-97, 1997). In the present
study, we tested the hypothesis that ceramide mediates TNF-
-induced
vasodilation. In phenylephrine-contracted rat thoracic aortic rings (no
endothelium), TNF-
caused concentration-dependent relaxation in the
presence of cyclooxygenase and lipoxygenase inhibitors. The
phospholipase A2 antagonist
7,7-dimethyl-(5Z,8Z)-eicosadienoic acid (DEDA; 50 µM) and the nonselective
PLA2 antagonist quinacrine (30 µM) inhibited TNF-
-induced relaxation. In cultured rat aortic vascular smooth muscle cells, TNF-
(10
7 g/ml) increased
intracellular ceramide 1.5-fold over basal level (0.08 nmol/mg
protein), which was blocked by the
PLA2 antagonist DEDA (50 µM). We
conclude that PLA2 activation and
increased ceramide generation play a role in mediating TNF-
-induced
endothelium-independent vasodilation.
cytokines; smooth muscle relaxation; sphingolipid signaling; sepsis
| |
INTRODUCTION |
|---|
|
|
|---|
CYTOKINES SUCH AS tumor necrosis factor-
(TNF-
)
have been shown to have both endothelium-dependent and -independent
vasodilator properties (14, 36). Such properties imply an important
role for TNF-
-induced vascular responses in cases in which plasma TNF-
levels are elevated such as sepsis/endotoxemia, vascular damage
associated with hypertension, and obesity (5, 8, 39). Indeed, the
vasodilator effects of TNF-
may be responsible for the marked
hypotension seen in septic shock. The endothelium-dependent component
has been attributed to activation of endothelial nitric oxide (NO)
synthase, generation of NO, and relaxation of vascular smooth muscle
(3, 34). The endothelium-independent component of TNF-
-induced
vasodilation has not been characterized.
In other systems, TNF-
has been shown to stimulate a
membrane-associated, neutral-optimum pH-acting sphingomyelinase
(nSMase) resulting in hydrolysis of sphingomyelin and generation of
ceramide and phosphocholine (19). Additionally, evidence demonstrates that arachidonic acid generated by membrane-associated phospholipase A2
(PLA2) may be a mediator of the
signal from the TNF-
receptor to nSMase (16). Ceramide is a
sphingolipid second messenger implicated in transducing the cellular
signals initiated by TNF-
in other physiological systems, but a role
for ceramide in mediating the effects of TNF-
in the vasculature has
not been investigated.
Ceramide generated through hydrolysis of membrane sphingomyelin is structurally very similar to diacylglycerol, a product of phosphoinositide-phospholipase C activity. Ceramide has been shown to activate a serine/threonine-specific protein phosphatase of the protein phosphatase 2A family (ceramide-activated protein phosphatase), a serine/threonine proline-directed protein kinase (ceramide-activated protein kinase), and inhibit translocation of phorbol ester-sensitive isoforms of the classic protein kinase C (PKC) family (6, 23, 18). The latter function in vascular smooth muscle implies a vasodilator role for ceramide, given the contraction-promoting nature of PKC in vascular smooth muscle. We have previously shown that exogenously applied cell-permeant ceramide and nSMase result in concentration-dependent vasodilation in contracted isolated rat thoracic aortic rings and that nSMase treatment of cultured vascular smooth muscle cells elicits intracellular ceramide generation (17).
We hypothesized that ceramide signaling mediates TNF-
-induced
vasodilation. To address this hypothesis, we tested the following specific aims: 1) to verify that
TNF-
causes endothelium-independent vasodilation,
2) to determine whether
TNF-
-induced vasodilation is
PLA2 dependent,
3) to determine whether TNF-
causes ceramide generation in cultured vascular smooth muscle cells,
and 4) to determine whether
TNF-
-induced ceramide generation is
PLA2 dependent. The hypothesized
signaling pathway is illustrated in Fig. 1.
|
| |
METHODS |
|---|
|
|
|---|
Isolated vascular segment preparation.
Male Sprague-Dawley rats (Charles River) weighing 200-250 g were
anesthetized with pentobarbital sodium (50 mg/kg ip), and aortas were
removed and placed under a dissecting microscope in cold physiological
salt solution (PSS; 130 mM NaCl, 4.5 mM KCl, 1.18 mM
KHPO4, 1.17 mM
MgSO4, 1.6 mM
CaCl2 · 2H2O,
14.9 mM NaHCO3, 5.5 mM dextrose,
and 0.03 mM CaNa2 EDTA). The
vessels were then cleaned of adherent fat and connective tissue and cut
into rings (4 mm long). The endothelium was removed from aortic
segments by a gentle rubbing procedure with the tips of a pair of
forceps. These rings were mounted in an organ chamber containing PSS
aerated with 95% O2-5%
CO2 for measurement of isometric
force development. The absence of endothelium was functionally
evaluated by relaxation to acetylcholine
(10
7 M) after contraction
in response to phenylephrine
(10
8 M). All preparations
were allowed to equilibrate for 90 min under a constant passive force
(~3 g) before an experiment was begun. This level of passive force
was determined to be optimal for maximal force development to
10
6 M phenylephrine. All
experiments were conducted in the presence of indomethacin
(10
5 M) to inhibit
cyclooxygenase. In some experiments, eicosatrienoic acid was added to
inhibit lipoxygenase.
Muscle bath experimental protocols.
After aortic ring preparation, a concentration-response curve to
phenylephrine (10
9 to
10
5 M) was constructed to
determine the EC50 contractile
response. After the effects of phenylephrine were washed out, vessel
segments were contracted with an
EC50 concentration of
phenylephrine. When the contraction reached a plateau phase, a
relaxation response to human recombinant TNF-
was conducted in
either the presence or absence of drugs to inhibit
PLA2. The
PLA2 inhibitors tested were
7,7-dimethyl-(5Z,8Z)-eicosadienoic
acid (DEDA) and quinacrine. Relaxation to cell-permeant ceramide was
also tested by addition of C2-ceramide
(10
5 M) or ethanol vehicle
to the plateau phase of a contraction to an
EC50 concentration of phenylephrine.
Cell culture.
Vascular smooth muscle cells were isolated and cultured by
explantation. Thoracic aortas from male Sprague-Dawley rats were removed and cleaned of adherent fat and connective tissue. Aortic segments were cut lengthwise, and the endothelium was removed by a
gentle rubbing procedure with a cotton swab moistened with PSS.
Segments were washed three times in sterile PSS and cut into small
pieces that were seated in DMEM supplemented with 30% fetal bovine
serum. After a 7- to 10-day period of cell proliferation, vessel
segments were removed, and cells were passaged upon confluency. Cells
were maintained in 10-cm plates through 10 passages in DMEM supplemented with 10% fetal bovine serum. The presence of
-actin was confirmed by staining with a FITC-conjugated anti-
-actin antibody and fluorescence microscopy.
Extraction of cellular lipids.
Lipids were extracted from vascular smooth muscle cells using the
methods of Van Veldoven and Bell (37). Briefly, after treatment with
human recombinant TNF-
, cells were rinsed three times with cold
phosphate-buffered saline and scraped in 4 ml ice-cold methanol.
Chloroform and water were added to make the chloroform-methanol-water
ratio 1:2:0.8. Samples were sonicated and centrifuged at 3,000 rpm for
30 min. The supernatant was transferred to another tube, and chloroform
and 1 M NaCl were added to make the chloroform-methanol-NaCl ratio
2:1:0.8. The pellet was reserved for measurement of cellular protein
using a Bio-Rad assay kit. Samples were vortexed and centrifuged at
1,500 rpm for 5 min to partition the aqueous from the organic fraction.
The lower layer (organic layer) was isolated and dried under nitrogen.
Measurement of intracellular ceramide.
Ceramide levels were determined using modified methods described by
Preiss et al. (29). Briefly, dried lipid extracts were solubilized in
20 µl of a solution of 7.5%
octyl-
-D-glucopyranoside and
5 mM cardiolipin in 1 mM diethylenetriaminepentaacetic acid. After a
10-min incubation period at room temperature, 50 µl of reaction
mixture (100 mM imidazole HCl, 100 mM NaCl, 25 mM
MgCl2, and 2 mM EGTA) and 20 µl
dithiothreitol (10 mM) were added to each sample. The enzymatic step
was initiated with the addition of 10 µl of a 1:1 solution of
Escherichia coli diacylglycerol kinase
(13 U/mg protein) reaction mixture and 10 µl of a 1:100 solution of
[
-32P]ATP
(0.5-1.0 µCi/nmol) with 10 mM ATP. After a 45-min incubation period at 25°C, the reaction was stopped with 4 ml of
chloroform-methanol (1:1) and 1 ml of 1 M NaCl. Samples were
centrifuged for 5 min at 1,500 rpm for partitioning. The lower organic
layer was isolated and washed with 2 ml perchloric acid (1%), and
samples were centrifuged at 1,500 rpm for 5 min. The perchloric acid
wash was repeated, and the organic layer was isolated and dried under
nitrogen. Ceramide-1-phosphate was resolved using high-performance
thin-layer chromatography (HPTLC) with a solution containing
chloroform-acetone-methanol-acetic acid-water (10:4:3:2:1). HPTLC
plates were exposed to phosphorimager screens, and ceramide-1-phosphate
levels were quantitated with a phosphorimager. Ceramide values were
normalized to amount of cellular protein.
Chemicals.
Human recombinant TNF-
, phenylephrine HCl, acetylcholine,
indomethacin, sodium nitroprusside,
N-acetylsphingosine (C2-ceramide), quinacrine, dithiothreitol, diethylenetriaminepentaacetic acid, anti-
-actin antibody,
octyl-
-D-glucopyranoside,
imidazole, and DEDA were purchased from Sigma Chemical (St. Louis, MO).
Cardiolipin was purchased from Avanti Polar Lipids (Alabaster, AL).
E. coli diacylglycerol
kinase and eicosatrienoic acid were purchased from Calbiochem (La
Jolla, CA). The protein assay kit was purchased from Bio-Rad
Laboratories (Hercules, CA).
Statistics. For muscle bath experiments, data are presented as means ± SE. For ceramide measurements, data are presented as means ± SE of triplicate replicates from one of three experiments with similar results. For two-group comparisons, Student's t-test was used with a P value <0.05 being considered significant. In multiple-testing procedures, the Bonferroni correction was applied.
| |
RESULTS |
|---|
|
|
|---|
TNF-
and cell-permeant ceramide induce
endothelium-independent vasodilation.
Experiments were carried out to evaluate the endothelium-independent
effects of TNF-
on contracted rat thoracic aortic segments. Figure
2A is a
representative tracing from an experiment illustrating the effect of
10
8 g/ml TNF-
on a
phenylephrine-contracted rat thoracic aortic ring denuded of
endothelium. In all experiments, detectable relaxation occurred within
5-15 min after stimulation with TNF-
. Figure 2B illustrates the vasodilatory effect
of cell-permeant ceramide (C2-ceramide;
10
5 M) in a
phenylephrine-contracted rat thoracic aortic ring (no endothelium). The
concentration of phenylephrine used was that which elicited a
half-maximal (EC50) contraction.
All muscle bath experiments were carried out in the presence of
indomethacin (10
5 M), a
cyclooxygenase antagonist. Incubation of aortic segments with an
inhibitor of 5- and 12-lipoxygenase, 5,8,11-eicosatrienoic acid (20 µM), did not affect relaxation to TNF-
(data not shown).
|
Effect of PLA2 inhibition on
TNF-
-induced vasodilation.
If the vasodilator effects of TNF-
are dependent on
PLA2, then inhibition of
PLA2 with pharmacological
antagonists should result in inhibition of TNF-
-induced
vasodilation. Figure
3A illustrates concentration-dependent vasodilation by TNF-
in
phenylephrine-contracted aortic rings denuded of endothelium.
Preincubation of the vessel segments with quinacrine (30 µM) for 30 min resulted in complete inhibition of TNF-
-induced vasodilation and
a small degree of contraction with increasing concentrations of
TNF-
. This concentration of quinacrine represents an average
IC50 concentration for
PLA2 inhibition based on work by
other investigators (10, 38). Incubation of aortic segments with DEDA
(50 µM) for 30 min resulted in inhibition of TNF-
-induced
vasodilation at TNF-
concentrations of
10
9, 3 × 10
9, and
10
8 g/ml (30, 45, and 50%,
respectively). Incubation of aortic segments with DEDA (50 µM) did
not affect relaxation to sodium nitroprusside (data not shown). The
inhibition of TNF-
-induced relaxation by DEDA was concentration
dependent (Fig. 3B). A submaximal
concentration of TNF-
(3 × 10
9 g/ml) was used to relax
phenylephrine-contracted (EC50)
aortic segments, followed by a concentration-response treatment with DEDA during a plateau phase of relaxation.
|
TNF-
increases intracellular ceramide levels in
cultured vascular smooth muscle cells.
Based on the muscle bath results in which TNF-
caused
endothelium-independent,
PLA2-dependent relaxation, we
investigated whether TNF-
would cause an increase in intracellular
ceramide levels. Cultured vascular smooth muscle cells from rat
thoracic aorta were treated with TNF-
(10
7 g/ml) for 5, 15, and
30 min. Cellular lipids were extracted, and intracellular ceramide
levels were measured as described in METHODS. Figure
4A
illustrates the increase in intracellular ceramide seen in the
phosphorimager scan of the HPTLC analysis. Incubation of vascular
smooth muscle cells with TNF-
resulted in a 1.5-fold increase in
intracellular ceramide at 15 min and a subsequent reduction at 30 min
(Fig. 4B). Time points beyond 30 min
were not investigated. Under basal conditions, cultured vascular smooth muscle cells contained 0.075 ± 0.003 nmol ceramide/mg protein.
|
Inhibition of PLA2 with DEDA blocks
TNF-
-induced ceramide generation.
To investigate the involvement of
PLA2 in TNF-
-induced ceramide
generation, we used an inhibitor of membrane-associated
PLA2, DEDA. Cultured vascular
smooth muscle cells were treated with vehicle (0.01% ethanol), DEDA
alone, or DEDA in combination with 10
7 g/ml TNF-
(DEDA
concentration, 50 µM) for the intervals indicated. Vehicle alone had
no effect on intracellular ceramide levels. Figure
5 illustrates blockade of TNF-
-induced
ceramide generation by DEDA.
|
| |
DISCUSSION |
|---|
|
|
|---|
The purpose of this study was to examine a possible signal transduction
mechanism mediating the endothelium-independent effects of TNF-
in
the vasculature. The overall hypothesis was that ceramide signaling
mediates endothelium-independent vasodilation to TNF-
. The main
findings from this study were that TNF-
elicits
endothelium-independent relaxation, which is dependent on
PLA2 and that TNF-
elicits PLA2-dependent ceramide generation
in cultured vascular smooth muscle cells, implying a role for
TNF-
-induced ceramide signaling in the vasculature (Fig. 1).
TNF-
and vascular reactivity.
It has been well documented that TNF-
causes vasodilation in a
number of vascular preparations (3, 11, 34). Previous work by others
was presumably undertaken to examine the vascular role of TNF-
during the severe hypotension that accompanies sepsis and endotoxemia,
cases in which plasma levels of TNF-
are markedly increased (8, 36).
More recent studies implicate TNF-
as a potential regulator of blood
pressure. Ferreri et al. (9) document increased TNF-
production in
medullary thick ascending limb tubules from angiotensin II-dependent
hypertensive rats. In addition, treatment of these rats with anti-TNF
antiserum potentiates the increase in mean arterial pressure seen in
this model of hypertension, implying a counterregulatory mechanism for
TNF-
against the pressor effect of angiotensin II (9). The
vasodilatory effects of TNF-
have been most commonly attributed to
endothelium-dependent generation of NO and subsequent relaxation of
vascular smooth muscle (3, 34). However, Hollenberg et al. (14) showed
that maximal inhibition of endothelial nitric oxide synthase with
NG-nitro-L-arginine
and blockade of cyclooxygenase with indomethacin did not completely
inhibit the relaxation response of rat aortic rings to TNF-
(14).
Indeed, in the present study, we have verified that both TNF-
and
cell-permeant ceramide elicit a marked relaxation in blood vessel
segments devoid of endothelium in the presence of indomethacin.
Therefore, it is clear that another yet uncharacterized mechanism is
responsible for endothelium-independent, cyclooxygenase-independent relaxation of vascular smooth muscle in response to TNF-
. We have
previously demonstrated that ceramide and exogenously applied sphingomyelinase cause relaxation of contracted rat thoracic aortic rings in the absence of endothelium (17). Therefore, if TNF-
increases ceramide production in vascular smooth muscle, it is possible
that the endothelium-independent mechanism for TNF-
-induced relaxation involves ceramide signaling.
TNF-
and ceramide generation.
Early studies investigating a relationship between cytokines and
sphingolipid signaling documented a TNF-
-induced increase in
intracellular ceramide with a concomitant decrease in membrane sphingomyelin (19). A novel signaling cascade was discovered, in which
nSMase was activated in response to stimulation with TNF-
and other
cytokines such as interferon-
and interleukin-1
(2, 7, 19, 23,
24). Here, we have substantiated this causal relationship by
documenting TNF-
-induced ceramide generation in vascular smooth
muscle cells for the first time. In the present study, the increase in
ceramide in cultured vascular smooth muscle cells was transient, with
maximum levels detected after 15 min of treatment with TNF-
. The
time course of the increase in ceramide levels in response to cytokines
is variable among various cell types. In HL-60 cells, Kim et al. (19)
showed that sphingomyelin turnover reached a maximum 1 h after
stimulation with 30 nM TNF-
and returned to control levels by 2 h.
In RINm5f cells, ceramide levels reach a maximum level at 5 min, which
returns to control levels after 20 min of stimulation with
interleukin-1
(40). In the present study, the time course of maximum
ceramide generation in the cultured rat aortic smooth muscle cells is
within the range of the time course of TNF-
-induced relaxation in
the muscle bath, where peak ceramide generation in cells and the
initiation of relaxation occurred within 15 min of exposure to the
cytokine. The increase in ceramide in the cultured smooth muscle cells
is transient, and levels return to baseline after 30 min, a time during
which relaxation to TNF-
is sustained in intact tissue segments.
might imply
that a transient relaxation response to TNF-
should occur, instead
of the plateaued relaxation phase we observed. One reason for this
apparent incongruity may be that ceramide generated by hydrolysis of
membrane sphingomyelin is known to interact with several possible
cellular targets. Among these are a ceramide-activated protein
phosphatase, ceramide-activated protein kinase, and PKC (6, 18, 23). It
is possible, therefore, that ceramide initiates a signaling cascade
involving one or more of these targets, resulting in a more sustained
effect downstream of ceramide generation. A second possibility is that
the TNF-
-induced ceramide generation profile in cultured smooth
muscle cells may differ from that which may occur in the intact vessel.
Studies have shown that vascular smooth muscle cells in culture lose
some of the phenotypic characteristics found in those of intact vessel
segments (32, 35). Such changes may contribute to the differences
between the cell culture and muscle bath data.
The magnitude of the ceramide response to TNF-
is in agreement with
other studies in which TNF-
- and other cytokine-induced ceramide
generation was investigated in different cell types. Between various
cell types, basal ceramide levels vary. Basal ceramide levels in our
cultured rat aorta smooth muscle cells were well within the range of
values stated by others regarding other cell types. Kim et al. (19)
documented that treatment of HL-60 cells resulted in a 1.4-fold
increase in intracellular ceramide after treatment with 30 nM TNF-
(10
11 g/ml). In EL4 thyoma
cells, interleukin-1
(40 ng/ml) induced a 1.3-fold increase in
ceramide (24). Basal ceramide values also may vary between different
groups of cells of the same cell type. Nakamura et al. (26) documented
basal ceramide levels ranging from ~1 to 3 nmol/mg protein in the
same study. We have previously reported basal ceramide levels of 0.3 nmol/mg protein in cultured rat thoracic aorta smooth muscle cells
(17). In this study, basal levels were 0.075 nmol/mg protein. One
explanation for this difference is that cells used for each study were
cultured from aortic explants from rats of different sources.
Role of PLA2.
TNF-
has been shown to stimulate
PLA2-mediated arachidonic acid
generation and subsequent ceramide generation in HL-60 cells and L929
cells (15, 16). Jayadev et al. (16) documented that exogenous melittin,
a PLA2 activator, or arachidonic
acid stimulates ceramide generation in HL-60 cells. The
PLA2 isoform responsible for this
effect of arachidonic acid is described as membrane associated and
melittin sensitive (22). The PLA2
antagonist inhibitor DEDA was chosen for this experiment because of its
specificity for the membrane-associated, melittin-specific isoform of
PLA2.
stimulates expression and activity
of other isoforms of PLA2,
including a cytosolic and secretory isoform (23, 24). Pharmacological
inhibitors such as methyl arachidonyl fluorophosphate are specific for
the calcium-dependent and -independent cytosolic isoform of
PLA2. In the present study, an
IC50 concentration of DEDA
partially blocked the relaxation response to TNF-
. Nonspecific
effects of DEDA are unlikely in this study, evidenced by the lack of
any effect of DEDA on sodium nitroprusside relaxation. An
IC50 concentration of quinacrine, a nonselective PLA2 antagonist,
completely blocked and partially reversed the relaxation response to
TNF-
. The partial reversal of the relaxation response may be because
of nonspecific effects of quinacrine on potassium channels (33). We
conclude that the melittin-sensitive isoform of
PLA2 is likely involved in the
endothelium-independent relaxation response to TNF-
, but the
involvement of other isoforms cannot be ruled out.
Arachidonic acid can be metabolized by 5- and 12-lipoxygenase to form
5-hydroxyeicosatetraenoic acid (5-HETE) and 12-hydroxyeicosatetraenoic acid (12-HETE), respectively (4). Both 5-HETE and 12-HETE are vasoactive (13), and to rule out contribution of these arachidonic acid
metabolites to the observed effect of TNF-
, we used a selective inhibitor of 5- and 12-lipoxygenase, eicosatrienoic acid. Because inhibition of lipoxygenase had no effect, we can rule out contribution of 5- and 12-HETE to TNF-
-induced vasodilation. Cyclooxygenase products were ruled out by the inclusion of indomethacin in all experiments.
In the cultured rat aortic smooth muscle cells, we observed complete
blockade of ceramide generation in response to TNF-
with an
IC50 concentration of DEDA.
Another interesting observation is that during treatment with DEDA and
TNF-
, ceramide levels decreased to 70% of control values at 15 min.
A possible explanation is that
PLA2 activity in unstimulated
cells might contribute to basal ceramide levels. We observed a slight
but statistically insignificant reduction in basal ceramide levels in
cells treated with DEDA alone for 30 min (data not shown). A more
likely explanation is that TNF-
stimulates a number of different
signaling pathways, including
PLA2, which may affect ceramide
generation by nSMase. Blockade of the
PLA2 component of TNF-
signaling, then, might allow a yet unknown inhibitory mechanism to
decrease nSMase activity and reduce ceramide levels.
Possible mechanism for TNF-
-induced
ceramide-mediated relaxation.
Although both TNF-
and ceramide have been shown to cause
endothelium-independent relaxation, a precise mechanism for
ceramide-mediated relaxation has not been characterized. The wide range
of intracellular targets for ceramide provides a number of possible
mechanisms for ceramide-mediated relaxation. Ceramide has been shown to
activate a serine/threonine-directed protein phosphatase of the protein phosphatase 2A family of phosphatases (6). Knapp et al. (20) showed
that inhibition of protein phosphatases 1A and 2A resulted in an
increase in tone of bovine coronary arterial rings, implying a relaxant
role for these enzymes.
in situ and activity of PKC-
in vitro (18,
21). The calcium-dependent isoforms of PKC are important for
contraction in vascular smooth muscle in response to adrenergic
agonists and other phospholipase C-linked vasoconstrictors (1, 12, 25).
The mode of ceramide-mediated inhibition is unknown but may be related
to structural similarity between ceramide and diacylglycerol. Ceramide
has been shown to interact directly with a zinc fingerlike lipid
binding domain of diacylglycerol kinase, an enzyme which shows
specificity for phosphorylating both ceramide and diacylglycerol (28).
This lipid-binding domain is very similar to the lipid-binding domain
of the phorbol ester-sensitive PKC family. Therefore, it is possible
that ceramide acts as a partial agonist for PKC, inhibiting the enzyme
by competitive antagonism in the presence of diacylglycerol.
In summary, the results from the present study indicate that isolated
rat aortic segments exhibit endothelium-independent vasodilation to
TNF-
that is partially dependent on
PLA2. This was demonstrated by
concentration-dependent inhibition of the relaxation response to
TNF-
by the PLA2 inhibitors
DEDA and quinacrine in endothelium-denuded rat thoracic aortic rings.
TNF-
also induced an increase in intracellular ceramide levels in
cultured vascular smooth muscle cells that was also
PLA2 dependent. From these
results, we conclude that ceramide signaling represents a novel
mechanism mediating the endothelium-independent vasodilatory effects of TNF-
.
| |
ACKNOWLEDGEMENTS |
|---|
These studies were supported by National Heart, Lung, and Blood Institute Grant HL-18575.
| |
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests: D. G. Johns, Dept. of Physiology, 7812 Medical Sciences Bldg. II, Univ. of Michigan Medical School, Ann Arbor, MI 48109-0622.
Received 3 April 1998; accepted in final form 14 July 1998.
| |
REFERENCES |
|---|
|
|
|---|
1.
Andrea, J. E.,
and
M. P. Walsh.
Protein kinase C of smooth muscle.
Hypertension
20:
585-595,
1992
2.
Ballou, L. R.,
C. P. Chao,
M. A. Holness,
S. C. Barker,
and
R. Raghow.
Interleukin-1-mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide.
J. Biol. Chem.
267:
20044-20050,
1992
3.
Baudry, N.,
and
E. Vicaut.
Role of nitric oxide in effects of tumor necrosis factor-alpha on microcirculation in rat.
J. Appl. Physiol.
75:
2392-2399,
1993
4.
Bonventre, J. V.
Phospholipase A2 and signal transduction.
J. Am. Soc. Nephrol.
3:
128-150,
1992[Abstract].
5.
Damas, P.,
J.-L. Canivet,
D. DeGroote,
Y. Vrindts,
A. Albert,
P. Franchimont,
and
M. Lamy.
Sepsis and serum cytokine concentrations.
Crit. Care Med.
25:
405-412,
1997[Medline].
6.
Dobrowsky, R. T.,
C. Kamibayashi,
M. C. Mumby,
and
Y. A. Hannun.
Ceramide activates heterotrimeric protein phosphatase 2A.
J. Biol. Chem.
268:
15523-15530,
1993
7.
Dressler, K. A.,
S. Mathias,
and
R. N. Kolesnick.
Tumor necrosis factor-alpha activates the sphingomyelin signal transduction pathway in a cell-free system.
Science
255:
1715-1718,
1992
8.
Ertel, W.,
M. H. Morrison,
P. Wang,
Z. F. Bah,
A. Ayala,
and
I. H. Chaudry.
The complex pattern of cytokines in sepsis: association between prostaglandins, cachectin, and interleukins.
Ann. Surg.
214:
141-148,
1991[Medline].
9.
Ferreri, N. R.,
Y. Zhao,
H. Takizawa,
and
J. C. McGiff.
Tumor necrosis factor-alpha-angiotensin interactions and regulation of blood pressure.
J. Hypertens.
15:
1481-1484,
1997[Medline].
10.
Frye, R. A.,
and
R. W. Holz.
Phospholipase A2 inhibitors block catecholamine secretion and calcium uptake in cultured bovine adrenal medullary cells.
Mol. Pharmacol.
23:
547-570,
1983[Abstract].
11.
Glembot, T. M.,
L. D. Britt,
and
M. A. Hill.
Endotoxin interacts with tumor necrosis factor alpha to induce vasodilation of isolated rat skeletal muscle arterioles.
Shock
5:
251-257,
1996[Medline].
12.
Haller, H.,
J. I. Smallwood,
and
H. Rasmussen.
Protein kinase C translocation in intact vascular smooth muscle strips.
Biochem. J.
270:
375-381,
1990[Medline].
13.
Harder, D. R.,
W. B. Campbell,
and
R. J. Roman.
Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone.
J. Vasc. Res.
32:
79-92,
1995[Medline].
14.
Hollenberg, S. M.,
R. E. Cunnion,
and
J. E. Parrillo.
The effect of tumor necrosis factor on vascular smooth muscle. In vitro studies using rat aortic rings.
Chest
100:
1133-1137,
1991
15.
Jayadev, S.,
H. L. Hayter,
N. Andrieu,
C. J. Gamard,
B. Liu,
R. Balu,
M. Hayakawa,
F. Ito,
and
Y. A. Hannun.
Phospholipase A2 is necessary for tumor necrosis factor-
-induced ceramide generation in L929 cells.
J. Biol. Chem.
272:
17196-17203,
1997
16.
Jayadev, S.,
C. M. Linardic,
and
Y. A. Hannun.
Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor.
J. Biol. Chem.
269:
5757-5763,
1994
17.
Johns, D. G.,
H. Osborn,
and
R. C. Webb.
Ceramide: a novel cell signaling mechanism for vasodilation.
Biochem. Biophys. Res. Commun.
237:
95-97,
1997[Medline].
18.
Jones, M. J.,
and
A. W. Murray.
Evidence that ceramide selectively inhibits protein kinase C-
translocation and modulates bradykinin activation of phospholipase D.
J. Biol. Chem.
270:
5007-5013,
1995
19.
Kim, M.-Y.,
C. Linardic,
L. Obeid,
and
Y. Hannun.
Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma interferon. Specific role in cell differentiation.
J. Biol. Chem.
266:
484-489,
1991
20.
Knapp, J.,
P. Boknik,
B. Linck,
H. Luss,
F. U. Muller,
P. Nacke,
J. Neumann,
U. Vahlensieck,
and
W. Schmitz.
The effect of the protein phosphatases inhibitor cantharidin on beta-adrenoreceptor-mediated vasorelaxation.
Br. J. Pharmacol.
120:
421-428,
1997[Medline].
21.
Lee, J. Y.,
Y. A. Hannun,
and
L. M. Obeid.
Ceramide inactivates cellular protein kinase C-alpha.
J. Biol. Chem.
271:
13169-13174,
1996
22.
Lister, M. D.,
K. B. Glaser,
R. J. Ulevitch,
and
E. A. Dennis.
Inhibition studies on the membrane-associated phospholipase A2 in vitro and prostaglandin E2 production in vivo of the macrophage-like P3881D1 cell. Effects of manoalide, 7,7-dimethyl-5,8-eicosadienoic acid, and p-bromophenacyl bromide.
J. Biol. Chem.
264:
8520-8528,
1989
23.
Mathias, S.,
K. A. Dressler,
and
R. N. Kolesnick.
Characterization of a ceramide-activated protein kinase: stimulation by tumor necrosis factor alpha.
Proc. Natl. Acad. Sci. USA
88:
10009-10013,
1991
24.
Mathias, S.,
A. Younes,
C. C. Kan,
I. Orlow,
C. Joseph,
and
R. N. Kolesnick.
Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta.
Science
259:
519-522,
1993
25.
Nakajima, S.,
M. Fujimoto,
and
M. Ueda.
Spatial changes of [Ca2+]i and contraction caused by phorbol esters in vascular smooth muscle cells.
Am. J. Physiol.
265 (Cell Physiol. 34):
C1138-C1145,
1993
26.
Nakamura, T.,
A. Abe,
K. J. Balazovich,
D. Wu,
S. J. Suchard,
L. A. Boxer,
and
J. A. Shayman.
Ceramide regulates oxidant release in adherent human neutrophils.
J. Biol. Chem.
269:
18384-18389,
1994
27.
Newton, R.,
L. M. Kuitert,
D. M. Slater,
I. M. Adcock,
and
P. J. Barnes.
Cytokine induction of cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells.
Life Sci.
60:
67-78,
1997[Medline].
28.
Pfeilschifter, J.,
C. Schalkwijk,
V. A. Briner,
and
H. van den Bosch.
Cytokine stimulated secretion of group II phospholipase A2 by rat mesangial cells. Its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells.
J. Clin. Invest.
92:
2516-2523,
1993.
29.
Preiss, J.,
C. R. Loomis,
W. R. Bishop,
R. Stein,
J. E. Neidel,
and
R. M. Bell.
Quantitative measurement of sn-1,2-diacylglycerols present in platelets, hepatocytes, and ras- and sis-transformed normal rat kidney cells.
J. Biol. Chem.
261:
8597-8600,
1986
30.
Preiss, J. E.,
C. R. Loomis,
R. M. Bell,
and
J. E. Niedel.
Quantitative measurement of sn-1,2-diacylglycerols.
Methods Enzymol.
141:
294-300,
1987[Medline].
31.
Redman, C.,
J. Lefevre,
and
M. L. MacDonald.
Inhibition of diacylglycerol kinase by the antitumor agent calphostin C. Evidence for the similarity between the active site or diacylglycerol kinase and the regulatory site of protein kinase C.
Biochem. Pharmacol.
50:
235-241,
1995[Medline].
32.
Rovner, A. S.,
R. A. Murphy,
and
G. K. Owens.
Expression of smooth muscle and nonmuscle myosin heavy chains in cultured vascular smooth muscle cells.
J. Biol. Chem.
261:
14740-14745,
1986
33.
Sakuta, H.,
and
I. Yoneda.
Inhibition by SKF 525A and quinacrine of endogenous glibenclamide-sensitive K+ channels in follicle-enclosed Xenopus oocytes.
Eur. J. Pharmacol.
252:
117-121,
1994[Medline].
34.
Shibata, M.,
H. Parfenova,
S. L. Zuckerman,
and
C. W. Leffler.
Tumor necrosis factor-alpha induces pial arteriolar dilation in newborn pigs.
Brain Res. Bull.
39:
241-247,
1996[Medline].
35.
Stadler, E., J. H. Campbell, and G. R. Campbell. Do cultured vascular smooth muscle cells resemble those
of the artery wall? If not, why not? J. Cardiovasc.
Pharmacol. 14, Suppl.:
S1-S8, 1989.
36.
Takahashi, K.,
K. Ando,
A. Ono,
T. Shimosawa,
T. Ogata,
and
T. Fujita.
Tumor necrosis factor-alpha induces vascular hyporesponsiveness in Spraque-Dawley rats.
Life Sci.
50:
1437-1444,
1992[Medline].
37.
Van Veldoven, P. P.,
and
R. M. Bell.
Effect of harvesting methods, growth conditions and growth phase on diacylglycerol levels in cultured human adherent cells.
Biochim. Biophys. Acta
959:
185-196,
1988[Medline].
38.
Wada, A.,
S. Sakuri,
H. Kobayashi,
N. Yanagihara,
and
F. Izumi.
Suppression by phospholipase A2 inhibitors of secretion of catecholamines from isolated adrenal medullary cells by suppression of cellular calcium uptake.
Biochem. Pharmacol.
32:
1175-1178,
1983[Medline].
39.
Wang, P.,
Z. F. Ba,
and
I. H. Chaudry.
Mechanism of hepatocellular dysfunction during early sepsis: key role of increased gene expression and release of proinflammatory cytokines tumor necrosis factor and interleukin-6.
Arch. Surg.
132:
364-370,
1997[Abstract].
40.
Welsh, N.
Interleukin-1beta-induced ceramide and diacylglycerol generation may lead to activation of the c-Jun NH2-terminal kinase and the transcription factor ATF2 in the insulin-producing cell line RINm5F.
J. Biol. Chem.
271:
8307-8312,
1996
This article has been cited by other articles:
![]() |
H. I. Abdullah, P. L. Pedraza, S. Hao, K. D. Rodland, J. C. McGiff, and N. R. Ferreri NFAT regulates calcium-sensing receptor-mediated TNF production Am J Physiol Renal Physiol, May 1, 2006; 290(5): F1110 - F1117. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Cheranov and J. H. Jaggar TNF-{alpha} dilates cerebral arteries via NAD(P)H oxidase-dependent Ca2+ spark activation Am J Physiol Cell Physiol, April 1, 2006; 290(4): C964 - C971. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Gulbins and P. L. Li Physiological and pathophysiological aspects of ceramide Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R11 - R26. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Tsai, M. Wang, M. Clauss, P. Sun, and D. R. Meldrum Endothelial monocyte-activating polypeptide II causes NOS-dependent pulmonary artery vasodilation: a novel effect for a proinflammatory cytokine Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2004; 287(4): R767 - R771. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Constable, G. W. Smith, G. E. Rottinghaus, M. E. Tumbleson, and W. M. Haschek Fumonisin-induced blockade of ceramide synthase in sphingolipid biosynthetic pathway alters aortic input impedance spectrum of pigs Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2034 - H2044. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Levade, N. Auge, R. J. Veldman, O. Cuvillier, A. Negre-Salvayre, and R. Salvayre Sphingolipid Mediators in Cardiovascular Cell Biology and Pathology Circ. Res., November 23, 2001; 89(11): 957 - 968. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Awasthi, J. Vivekananda, V. Awasthi, D. Smith, and R. J. King CTP:phosphocholine cytidylyltransferase inhibition by ceramide via PKC-{alpha}, p38 MAPK, cPLA2, and 5-lipoxygenase Am J Physiol Lung Cell Mol Physiol, July 1, 2001; 281(1): L108 - L118. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kleine, G. Liu, N. Leblanc, and R. L. Hebert Bradykinin stimulates ceramide production by activating specific BK-B1 receptor in rat small artery Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H175 - H183. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |